Company Profile
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest News
Brown-Forman turns down Sazerac takeover bid
Carlyle, Bain in race to buy Wealth Enhancement for $7bn – report
3 AI Stocks to Buy Now While They Are Still Cheap
PGIM to Acquire Remaining Interest in Deerpath Capital
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Website | https://www.freseniusmedicalcare.com |
| Audit Risk | 1 |
| Board Risk | 6 |
| Overall Risk | 4 |
| Market Cap | 11.71B |
| Trailing P/E | 13.34 |
| Forward P/E | 9.91 |
| Dividend Rate | 1.49 |
| Dividend Yield | 3.44% |
| Trailing Annual Div. Rate | 1.49 |
| Trailing Annual Div. Yield | 3.44% |
| Trailing EPS | 3.27 |
| Forward EPS | 4.4 |
| Book Value | 49.03 |
| Price-to-Book | 0.89 |
| Enterprise-to-Revenue | 1.16 |
| Enterprise-to-EBITDA | 8.64 |
| Ex-Dividend Date | 05/22/2026 |
| Earnings Date | 08/04/2026 |
| Earnings Call Date | 08/04/2026 |
| Earnings Average | 1.07 |
| Earnings Low | 0.9 |
| Earnings High | 1.3 |
| Revenue Average | 4.78B |
| Revenue Low | 4.75B |
| Revenue High | 4.83B |